P2X7 antagonist AZ10606120 and A2A antagonist SCH58261 were i.p. administered alone or in combination every three days, starting on the day of CRC i.v. inoculum (Fig. 4). The gene discussed is P2RX7; the disease is colorectal carcinoma.